Mass spectrometry synuclein detection in human plasma

Synucleins (alpha, beta, and gamma) are potential biomarkers for Parkinson’s disease dementia (PDD), Dementia of Lewy body (DLB) and the Multi system atrophy (MSA). Their quantification with Mass spectrometry (MS) represents an interesting approach as it can precisely quantify synuclein proteoforms including mutations, alternative splicing, phosphorylation and other post‐translational modifications.